Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OPTN 
OptiNose (OPTN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OPTN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -30.28% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 92.64M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 124478 | Beta -0.3 | 52 Weeks Range 4.82 - 21.45 | Updated Date 04/1/2025 |
52 Weeks Range 4.82 - 21.45 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-05 | When Before Market | Estimate -0.84 | Actual -0.03 |
Profitability
Profit Margin -27.54% | Operating Margin (TTM) 1.58% |
Management Effectiveness
Return on Assets (TTM) -8.63% | Return on Equity (TTM) -1050.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 137011928 | Price to Sales(TTM) 1.18 |
Enterprise Value 137011928 | Price to Sales(TTM) 1.18 | ||
Enterprise Value to Revenue 1.75 | Enterprise Value to EBITDA -4.33 | Shares Outstanding 10124300 | Shares Floating 6924275 |
Shares Outstanding 10124300 | Shares Floating 6924275 | ||
Percent Insiders 7.12 | Percent Institutions 72.16 |
Analyst Ratings
Rating 4.5 | Target Price 30.75 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OptiNose
Company Overview
History and Background
OptiNose was founded in 2000. The company focuses on developing and commercializing products for patients treated by ear, nose, and throat (ENT) specialists and allergists. Its key milestones include FDA approval and commercial launch of its XHANCE product.
Core Business Areas
- Pharmaceuticals: Develops and commercializes pharmaceutical products using its bi-directional nasal delivery technology.
Leadership and Structure
OptiNose's leadership team includes key executives responsible for research and development, commercialization, and finance. The organizational structure is typical of a publicly traded pharmaceutical company.
Top Products and Market Share
Key Offerings
- XHANCE: XHANCE is a nasal spray approved for the treatment of nasal polyps. Competitors include nasal steroids from companies like GSK (GSK), Teva (TEVA), and Regeneron/Sanofi (REGN/SNY). Market share data is dynamic and depends on prescription data and competitive dynamics, it is estimated around 25% in its class based on number of prescriptions.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on ENT and allergy treatments is competitive, with several players developing and marketing nasal sprays and other medications.
Positioning
OptiNose is positioned as a specialty pharmaceutical company focused on innovative nasal drug delivery. Its competitive advantage lies in its bi-directional nasal delivery technology.
Total Addressable Market (TAM)
The TAM for nasal polyp treatment is estimated to be billions of dollars. OptiNose, with its XHANCE product, aims to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Proprietary bi-directional nasal delivery technology
- Approved product (XHANCE)
- Focus on underserved ENT market
Weaknesses
- Reliance on single product (XHANCE) for revenue
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful commercialization of XHANCE
Opportunities
- Expanding indications for XHANCE
- Developing new products using bi-directional nasal delivery technology
- Partnering with larger pharmaceutical companies
Threats
- Competition from existing and new nasal sprays
- Pricing pressures from insurance companies
- Regulatory challenges
Competitors and Market Share
Key Competitors
- GSK
- TEVA
- REGN
- SNY
Competitive Landscape
OptiNose's advantages include its novel drug delivery technology and focus on the ENT market. Disadvantages include its smaller size and limited resources compared to larger pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data would be populated here if available.
Future Projections: Future growth projections depend on analyst estimates and would be populated here if available.
Recent Initiatives: Recent strategic initiatives include expanding the sales force for XHANCE and exploring new indications for the product.
Summary
OptiNose is a specialty pharmaceutical company with a focus on ENT. It has a unique delivery system in XHANCE, which helps with market penetration. The company's biggest weakness is its dependence on only one product. Optinose should look out for competitive pressure and pricing strategies from insurance companies.
Similar Companies
- GSK
- TEVA
- REGN
- SNY
Sources and Disclaimers
Data Sources:
- Company reports, SEC filings, market research reports, analyst estimates
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OptiNose
Exchange NASDAQ | Headquaters Yardley, PA, United States | ||
IPO Launch date 2017-10-13 | CEO & Director Dr. Ramy A. Mahmoud M.D., M.P.H. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 127 | Website https://www.optinose.com |
Full time employees 127 | Website https://www.optinose.com | ||
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.